Semaglutide Outperforms Rivals for Blood Sugar & Weight Loss

What Was This Study About?

Researchers compared three injectable diabetes medications — semaglutide, dulaglutide, and liraglutide — all belonging to a drug class called GLP-1 receptor agonists. These medications help lower blood sugar and can also support weight loss. The study used real-world patient data from multiple clinics in China between 2022 and 2024.

Who Was Included?

The study included 292 adults with type 2 diabetes who had recently started one of these three medications. Researchers carefully matched patients with similar health profiles to make fair comparisons between the groups.

What Did They Find?

Semaglutide (1.0 mg) produced greater reductions in HbA1c — a key measure of long-term blood sugar control — compared to both dulaglutide and liraglutide. Patients on semaglutide were also more likely to reach their blood sugar targets and lost more body weight.

Semaglutide was also linked to better long-term outcomes, including lower projected rates of death from any cause and cardiovascular (heart-related) death.

Were There Safety Differences?

Importantly, all three medications showed similar safety profiles — no significant differences in side effects were found between the groups. This suggests that while semaglutide may be more effective, it is not associated with additional risks compared to the other two medications.

What About Dulaglutide vs. Liraglutide?

When compared to each other, dulaglutide and liraglutide performed similarly in terms of blood sugar control and weight loss.

What Does This Mean for Patients?

If you are currently taking or considering a GLP-1 receptor agonist, this study suggests semaglutide may offer stronger benefits for blood sugar control and weight management. However, always speak with your doctor before making any changes to your diabetes treatment plan, as individual health needs vary.